中国全科医学2016，Vol.19Issue(12)：1361-1366,6.DOI:10.3969/j.issn.1007-9572.2016.12.001
嵌合抗原受体-T细胞免疫治疗在血液系统恶性肿瘤中的应用进展
Application of CAR-T Cell Immunotherapy in the Treatment of Hematological Malignancy
克晓燕1
作者信息
- 1. 100191 北京市，北京大学第三医院血液科
- 折叠
摘要
Abstract
Chimeric antigen receptor(CAR)connects single - chain variable fragment and activation motif of T cells, which allows modified T cells possess dual functions of recognizing tumor antigens in an MHC unrestricted way and killing the target cells. The intracellular structures of CAR has changed over time,from the first generation with the expression of single signal molecule,to the second and third generation adding one or two and multiple costimulatory endodomains,and to the fourth generation combining with the domains of coding CAR and/ or the promoter,and suicide gene. They enhance and regulate the persistence and cytotoxicity of modified T cells. This paper summarized the available data on the principle of CAR-T cell immunotherapy,its application in the treatment of hematological malignancy,and the main adverse reactions and response measures. It was found that chimeric antigen receptor - T(CAR-T)cells have received better therapeutic effect in many types of hematological malignancy,remarkably for the CAR-T cell immunotherapy targeting CD19;patients who adopt cell immunotherapy have prolonged survival,improved quality of life,and less adverse reactions. The main adverse reactions of CAR-T cell immunotherapy are on - target toxicity and cytokine release syndrome,which must be paid more attention.关键词
血液肿瘤/嵌合抗原受体/T 细胞/免疫治疗Key words
Hematologic neoplasms/Chimeric antigen receptor/T cell/Immnunotherapy分类
医药卫生引用本文复制引用
克晓燕..嵌合抗原受体-T细胞免疫治疗在血液系统恶性肿瘤中的应用进展[J].中国全科医学,2016,19(12):1361-1366,6.
